KLSE:NPS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Nova Pharma Solutions Berhad

Market Cap

RM34.3m

Last Updated

2021/08/03 11:03 UTC

Data Sources

Company Financials

Executive Summary

Nova Pharma Solutions Berhad provides technical documentation, validation, and project execution for pharmaceutical and biotechnology industries in Malaysia, Taiwan, Thailand, and Vietnam. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Nova Pharma Solutions Berhad's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: Insufficient data to determine NPS's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine NPS's volatility change over the past year.


Market Performance


7 Day Return

0%

NPS

-1.9%

MY Construction

-1.0%

MY Market


1 Year Return

n/a

NPS

-4.8%

MY Construction

-0.3%

MY Market

Return vs Industry: Insufficient data to determine how NPS performed against the MY Construction industry.

Return vs Market: Insufficient data to determine how NPS performed against the MY Market.


Shareholder returns

NPSIndustryMarket
7 Day0%-1.9%-1.0%
30 Day0%-3.0%-1.2%
90 Dayn/a-12.2%-5.8%
1 Yearn/a-1.4%-4.8%3.3%-0.3%
3 Yearn/a-20.4%-26.3%-3.3%-12.4%
5 Yearn/a-39.2%-47.6%8.4%-9.8%

Long-Term Price Volatility Vs. Market

How volatile is Nova Pharma Solutions Berhad's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Nova Pharma Solutions Berhad undervalued compared to its fair value and its price relative to the market?

3.47x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NPS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NPS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NPS is unprofitable, so we can't compare its PE Ratio to the MY Construction industry average.

PE vs Market: NPS is unprofitable, so we can't compare its PE Ratio to the MY market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NPS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NPS is overvalued based on its PB Ratio (3.5x) compared to the MY Construction industry average (0.8x).


Future Growth

How is Nova Pharma Solutions Berhad forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.2%

Forecasted Capital Goods industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nova Pharma Solutions Berhad has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Nova Pharma Solutions Berhad performed over the past 5 years?

-37.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NPS is currently unprofitable.

Growing Profit Margin: NPS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NPS is unprofitable, and losses have increased over the past 5 years at a rate of 37.2% per year.

Accelerating Growth: Unable to compare NPS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NPS is unprofitable, making it difficult to compare its past year earnings growth to the Construction industry (-24.6%).


Return on Equity

High ROE: NPS has a negative Return on Equity (-7.4%), as it is currently unprofitable.


Financial Health

How is Nova Pharma Solutions Berhad's financial position?


Financial Position Analysis

Short Term Liabilities: NPS's short term assets (MYR11.5M) exceed its short term liabilities (MYR1.9M).

Long Term Liabilities: NPS's short term assets (MYR11.5M) exceed its long term liabilities (MYR45.2K).


Debt to Equity History and Analysis

Debt Level: NPS is debt free.

Reducing Debt: NPS had no debt 5 years ago.

Debt Coverage: NPS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: NPS has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Nova Pharma Solutions Berhad current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NPS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NPS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NPS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NPS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: NPS is not paying a notable dividend for the MY market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NPS's dividend in 3 years as they are not forecast to pay a notable one for the MY market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.1yrs

Average management tenure


CEO

Boo-Wie Khoo (51 yo)

no data

Tenure

Mr. Khoo Boo Wie serves as Chief Executive Officer and Executive Director of Nova Pharma Solutions Berhad. In year 2005, he joined Nova Pharma as an Engineering and Project Manager. He was promoted to Gene...


Leadership Team

Experienced Management: NPS's management team is considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Nova Pharma Solutions Berhad's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nova Pharma Solutions Berhad
  • Ticker: NPS
  • Exchange: KLSE
  • Founded: 1977
  • Industry: Construction and Engineering
  • Sector: Capital Goods
  • Market Cap: RM34.272m
  • Shares outstanding: 149.01m
  • Website: https://novapharmasolutions.com

Number of Employees


Location

  • Nova Pharma Solutions Berhad
  • Sky Park One City
  • Suite C-5-1 & 2
  • Subang Jaya
  • Selangor
  • 47650
  • Malaysia

Listings


Biography

Nova Pharma Solutions Berhad provides technical documentation, validation, and project execution for pharmaceutical and biotechnology industries in Malaysia, Taiwan, Thailand, and Vietnam. The company offe...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/08/03 11:03
End of Day Share Price2021/06/18 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.